Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 3,594 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetes Mellitus, Type 2, Impaired Renal Function
Interventions
Dapagliflozin 10 MG [Farxiga]
Drug
Lead sponsor
Emerald Clinical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Recruiting Not applicable Interventional Accepts healthy volunteers

Extracellular Vesicles, Insulin Action, and Exercise

NCT06546085
Conditions
Type 2 Diabetes, Obesity
Interventions
Exercise
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
30 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
3
States / cities
New Brunswick, New Jersey
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacogenomics of Thiazolidinediones

NCT01135394
Conditions
Type 2 Diabetes
Interventions
Pioglitazone
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
35 Years to 64 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Diabetes Mellitus
Interventions
nutritional herbal extract from Salacia oblonga
Drug
Lead sponsor
Ross Products
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
2
States / cities
Edina, Minnesota • Cincinnati, Ohio
Conditions
Type 2 Diabetes, Diabetic Cardiomyopathy, Heart Failure, Cardiometabolic Diseases
Interventions
Intensive Prevention Strategy
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Dallas, Texas
Conditions
Osteoarthritis, Knee, Diabetes Mellitus, Type 2
Interventions
triamcinolone acetonide extended-release injectable suspension; TCA-ER, Triamcinolone Acetonide- Immediate Release;TCA-IR
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
40 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Type 2 Diabetes
Interventions
Medical Nutrition Therapy Intervention
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bloomington, Indiana
Conditions
Type 2 Diabetes
Interventions
FAMS 2.0, Print Materials
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Type II Diabetes, Periodontal Disease
Interventions
Triclosan containing toothpaste, Non-triclosan containing toothpaste
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Completed Phase 3 Interventional Results available

Phase 3 Alogliptin Pediatric Study

NCT02856113
Conditions
Diabetes Mellitus, Type 2
Interventions
Alogliptin Benzoate, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
10 Years to 17 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
34
States / cities
Little Rock, Arkansas • Los Angeles, California • Palmdale, California + 31 more
Completed Phase 2 Interventional Accepts healthy volunteers

Pistachios Blood Sugar Control, Heart and Gut Health

NCT04056208
Conditions
Type 2 Diabetes, Cardiovascular Diseases
Interventions
Pistachio, Usual care
Drug · Other
Lead sponsor
Penn State University
Other
Eligibility
30 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
University Park, Pennsylvania
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Assessing the Value of Avocados on Glycemic Control in Type 2 Diabetes

NCT05958368
Conditions
Diabetes Mellitus, Type 2, Insulin, Fructosamine, C-Reactive Protein, Glucose, Overweight and Obesity
Interventions
Avocado, Other Fruit(s)
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Type 2 Diabetes Mellitus, T2DM
Interventions
HM15275, Placebo of HM15275
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
20
States / cities
Mesa, Arizona • Santa Clarita, California • DeLand, Florida + 14 more
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
38
States / cities
Anniston, Alabama • Birmingham, Alabama • Pell City, Alabama + 30 more
Terminated Not applicable Interventional Accepts healthy volunteers

Resveratrol in Type2 Diabetes and Obesity

NCT01158417
Conditions
Type 2 Diabetes, Obesity, Insulin Resistance
Interventions
Placebo, Resveratrol 40 mg oral three times a day, Resveratrol 500 mg oral once daily.
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
20 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Williamsville, New York
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK1362885, Glucagon, Glucagon + GSK1362885
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
PreDiabetes
Interventions
Standard NDPP, Very low-carbohydrate diet
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 75 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Overweight, Obesity, Type 2 Diabetes
Interventions
Tirzepatide, Zenagamtide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Conditions
Diabetes Mellitus, Non-Insulin-Dependent, Hypertensive Disease
Interventions
Liraglutide or Placebo
Drug
Lead sponsor
Tulane University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Conditions
Type 2 Diabetes, Obesity, Cannabis Use, Insulin Sensitivity
Interventions
Study A: Single use of cannabis flower product, Study B: Ad libitum cannabis use for four weeks or no cannabis use
Other
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
21 Years to 40 Years
Enrollment
233 participants
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boulder, Colorado
Completed Phase 2 Interventional Results available

Uric Acid Lowering Trial in Youth Onset T2D

NCT03899883
Conditions
Diabetic Kidney Disease, Hyperuricemia, Diabetes, Diabetes Mellitus, Type 2, Type2 Diabetes, Type 2 Diabetes Mellitus, Diabetic Nephropathies, Diabetes Complications
Interventions
Pegloticase 8 MG/ML [Krystexxa]
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 25 Years · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Diabetes Mellitus Type 2
Interventions
Adult enteral formula
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Timeline
Started 2002
U.S. locations
2
States / cities
Chicago, Illinois • Charleston, North Carolina
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, insulin detemir, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 84 Years
Enrollment
987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
60
States / cities
Alexander City, Alabama • Birmingham, Alabama • Encino, California + 49 more
Conditions
Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Interventions
Metformin, Sulfonylurea, DPP-4 inhibitor, SGLT2 inhibitor, GLP1 receptor agonist
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
4,888 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Nashville, Tennessee